HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer
Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
ER and FGFR1 interaction critical in endocrine resistant breast cancer
Interrupting breast cancer treatment for young women who desire pregnancy
Editor's choice for December 2015
Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging
Novel estrogen receptor-targeting agent represents ‘quantum leap’
Ductal carcinoma in situ: Anastrozole versus tamoxifen
Update on management of the axilla